Ikena Oncology Announces Stockholder Approval Of Merger With Inmagene Biopharmaceuticals
ReutersJul 15, 2025 8:48 PM
July 15 (Reuters) - Ikena Oncology Inc IKNA.O:
IKENA ONCOLOGY ANNOUNCES STOCKHOLDER APPROVAL OF MERGER WITH INMAGENE BIOPHARMACEUTICALS
IKENA ONCOLOGY INC - ANNOUNCES 1-FOR-12 REVERSE STOCK SPLIT
IKENA ONCOLOGY INC - COMBINED COMPANY TO TRADE ON NASDAQ AS 'IMA'
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
The Coca-Cola Company 2025 Second Quarter Earnings Preview
Coca-Cola’s total revenue for Q2 2025 is projected to reach $12.55 billion, representing a 1.95% increase from $12.31 billion in Q2 2024. The expected earnings per share (EPS) for Q2 2025 is $0.84, flat compared to Q2 2024, indicating zero growth.TradingKey
10 hours ago
What Is Stellar (XLM), and Why Did It Surge Over 110% in Just 7 Days?
Stellar isn’t just another altcoin — it’s a blueprint for a next-generation financial system. From remittances and stablecoin settlement to smart contracts and CBDC infrastructure, Stellar is redefining what “on-chain capital markets” can look like.TradingKey
11 hours ago
Stablecoins — The New Era of Financial “Colonization” and the Last Bastion of Dollar Dominance
TradingKey - On May 20, the U.S. Senate passed preliminary procedural votes on the “Guidance and Establishment of a National Stablecoin Innovation Act” (commonly known as the Stablecoin “Genius Act”).TradingKey
16 hours ago
Eurozone June Harmonised Inflation Commentary: Short-Term Profit Potential for Euro Bulls
TradingKey - On 17 July 2025, the Eurozone's June Harmonised Inflation data was released, aligning with market expectations. The headline HICP rose slightly from 1.9% in May to 2.0%, while core HICP remained steady at 2.3%.TradingKey
16 hours ago
Wells Fargo Q1 2025: Is it a Fragile Fortress or a Mispriced Revival
TradingKey - Wells Fargo's (WFC) Q1 2025 results present a paradox: resiliency without momentum. Net income on the surface was up 6% year-over-year at $4.9 billion, which is $1.39 a diluted share for a 16% EPS lift driven by forceful share repurchases.TradingKey
Thu, May 1
Tradingkey
